Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles.
Serwanga J, Oluka GK, Baine C, Ankunda V, Sembera J, Kato L, Katende JS, Odoch G, Auma BO, Gombe B; COVID-19 Immunoprofiling Team; Musenero M, Kaleebu P. Serwanga J, et al. Among authors: ankunda v. PLoS One. 2024 Jul 29;19(7):e0303113. doi: 10.1371/journal.pone.0303113. eCollection 2024. PLoS One. 2024. PMID: 39074077 Free PMC article.
The single-dose Janssen Ad26.COV2.S COVID-19 vaccine elicited robust and persistent anti-spike IgG antibody responses in a 12-month Ugandan cohort.
Serwanga J, Kato L, Oluka GK, Ankunda V, Sembera J, Baine C, Kitabye I, Namuyanja A, Opio S, Katende JS, Ejou P; COVID-19 Immunoprofiling Team; Kaleebu P. Serwanga J, et al. Among authors: ankunda v. Front Immunol. 2024 May 8;15:1384668. doi: 10.3389/fimmu.2024.1384668. eCollection 2024. Front Immunol. 2024. PMID: 38779677 Free PMC article.
The subdued post-boost spike-directed secondary IgG antibody response in Ugandan recipients of the Pfizer-BioNTech BNT162b2 vaccine has implications for local vaccination policies.
Ankunda V, Katende JS, Oluka GK, Sembera J, Baine C, Odoch G, Ejou P, Kato L; COVID-19 Immunoprofiling Team; Kaleebu P, Serwanga J. Ankunda V, et al. Front Immunol. 2024 Feb 16;15:1325387. doi: 10.3389/fimmu.2024.1325387. eCollection 2024. Front Immunol. 2024. PMID: 38469296 Free PMC article.
Sustained S-IgG and S-IgA antibodies to Moderna's mRNA-1273 vaccine in a Sub-Saharan African cohort suggests need for booster timing reconsiderations.
Serwanga J, Ankunda V, Katende JS, Baine C, Oluka GK, Odoch G, Nantambi H, Mugaba S, Namuyanja A, Ssali I, Ejou P, Kato L; COVID-19 Immunoprofiling Team; Musenero M, Kaleebu P. Serwanga J, et al. Among authors: ankunda v. Front Immunol. 2024 Jan 31;15:1348905. doi: 10.3389/fimmu.2024.1348905. eCollection 2024. Front Immunol. 2024. PMID: 38357547 Free PMC article.
Sustained spike-specific IgG antibodies following CoronaVac (Sinovac) vaccination in sub-Saharan Africa, but increased breakthrough infections in baseline spike-naive individuals.
Sembera J, Baine C, Ankunda V, Katende JS, Oluka GK, Akoli CH, Kato L, Odoch G, Ejou P, Opio S, Musenero M; COVID-19 Immunoprofiling Team; Kaleebu P, Serwanga J. Sembera J, et al. Among authors: ankunda v. Front Immunol. 2023 Nov 30;14:1255676. doi: 10.3389/fimmu.2023.1255676. eCollection 2023. Front Immunol. 2023. PMID: 38098482 Free PMC article.
Spike protein is a key target for stronger and more persistent T-cell responses-a study of mild and asymptomatic SARS-CoV-2 infection.
Ssali I, Mugaba S, Watelo AK, Bemanzi J, Katende JS, Oluka GK, Ankunda V, Baine C, Kato L; COVID-19 Immunoprofiling Team; Onyachi N, Muwanga M, Jjuuko M, Kayiwa J, Nsereko C, Auma BO, Weiskopf D, Sette A, Lutalo T, Musenero M, Kaleebu P, Serwanga J. Ssali I, et al. Among authors: ankunda v. Int J Infect Dis. 2023 Nov;136:49-56. doi: 10.1016/j.ijid.2023.09.001. Epub 2023 Sep 6. Int J Infect Dis. 2023. PMID: 37683720 Free article.
Seroprevalence and durability of antibody responses to AstraZeneca vaccination in Ugandans with prior mild or asymptomatic COVID-19: implications for vaccine policy.
Serwanga J, Baine C, Mugaba S, Ankunda V, Auma BO, Oluka GK, Kato L, Kitabye I, Sembera J, Odoch G, Ejou P, Nalumansi A, Gombe B, Musenero M, Kaleebu P. Serwanga J, et al. Among authors: ankunda v. Front Immunol. 2023 May 2;14:1183983. doi: 10.3389/fimmu.2023.1183983. eCollection 2023. Front Immunol. 2023. PMID: 37205095 Free PMC article.
Pre-pandemic SARS-CoV-2-specific IFN-γ and antibody responses were low in Ugandan samples and significantly reduced in HIV-positive specimens.
Nantambi H, Sembera J, Ankunda V, Ssali I, Kalyebi AW, Oluka GK, Kato L, Ubaldo B, Kibengo F, Katende JS, Gombe B, Baine C, Odoch G, Mugaba S, Sande OJ; COVID-19 Immunoprofiling Team; Kaleebu P, Serwanga J. Nantambi H, et al. Among authors: ankunda v. Front Immunol. 2023 Apr 19;14:1148877. doi: 10.3389/fimmu.2023.1148877. eCollection 2023. Front Immunol. 2023. PMID: 37153598 Free PMC article.
Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months.
Serwanga J, Ankunda V, Sembera J, Kato L, Oluka GK, Baine C, Odoch G, Kayiwa J, Auma BO, Jjuuko M, Nsereko C, Cotten M, Onyachi N, Muwanga M, Lutalo T, Fox J, Musenero M, Kaleebu P; COVID-19 Immunoprofiling Team. Serwanga J, et al. Among authors: ankunda v. Front Immunol. 2023 Mar 16;14:1152522. doi: 10.3389/fimmu.2023.1152522. eCollection 2023. Front Immunol. 2023. PMID: 37006272 Free PMC article.
11 results